Vaxcyte Inc (NASDAQ: PCVX) on Friday, soared 0.37% from the previous trading day, before settling in for the closing price of $86.21. Within the past 52 weeks, PCVX’s price has moved between $53.83 and $121.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 5.63%. With a float of $120.32 million, this company’s outstanding shares have now reached $124.43 million.
In an organization with 254 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 2.95%, operating margin of -3662.28%, and the pretax margin is -3514.11%.
Vaxcyte Inc (PCVX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Vaxcyte Inc is 3.47%, while institutional ownership is 107.36%. The most recent insider transaction that took place on Dec 18 ’24, was worth 710,249. In this transaction PRESIDENT AND CFO of this company sold 8,000 shares at a rate of $88.78, taking the stock ownership to the 109,491 shares. Before that another transaction happened on Dec 18 ’24, when Company’s Officer proposed sale 8,000 for $89.83, making the entire transaction worth $718,640.
Vaxcyte Inc (PCVX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 5.63% per share during the next fiscal year.
Vaxcyte Inc (NASDAQ: PCVX) Trading Performance Indicators
Vaxcyte Inc (PCVX) is currently performing well based on its current performance indicators. A quick ratio of 17.88 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.68, a number that is poised to hit -1.10 in the next quarter and is forecasted to reach -4.66 in one year’s time.
Technical Analysis of Vaxcyte Inc (PCVX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.8 million. That was better than the volume of 0.92 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 15.58%. Additionally, its Average True Range was 3.74.
During the past 100 days, Vaxcyte Inc’s (PCVX) raw stochastic average was set at 31.78%, which indicates a significant increase from 20.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 36.92% in the past 14 days, which was lower than the 61.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $99.11, while its 200-day Moving Average is $84.72. However, in the short run, Vaxcyte Inc’s stock first resistance to watch stands at $88.20. Second resistance stands at $89.87. The third major resistance level sits at $90.85. If the price goes on to break the first support level at $85.56, it is likely to go to the next support level at $84.58. The third support level lies at $82.91 if the price breaches the second support level.
Vaxcyte Inc (NASDAQ: PCVX) Key Stats
Market capitalization of the company is 10.82 billion based on 124,637K outstanding shares. Right now, sales total 0 K and income totals -402,270 K. The company made 0 K in profit during its latest quarter, and -103,120 K in sales during its previous quarter.
